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Summary
This study assessed cellular and soluble markers of immune activation in HIV-1-seronegative men 
who have sex with men (MSM). MSM immune profiles were characterized by increased 
expression of CD57 on T cells and endotoxemia. Endotoxin presence was linked to recent high-
risk exposure and associated with elevated cytokine levels and decreased CD4/CD8 T cell ratios. 
Taken together, these data show elevated levels of inflammation linked to periods of endotoxemia 
resulting in a significantly different immune phenotype in a subset of MSM at high risk of HIV-1 
acquisition.
MSM represent approximately 2% of the US population, but account for approximately 63% 
of all new HIV-1 infections in the US [1]. Risk factors pertaining to MSM include anal 
intercourse [2], differences in transmission route and kinetics of viral dissemination [3], and 
inadequate access to preventative health care services [4-7]. Thus, MSM remain among the 
populations most highly affected by HIV-1 in both resource–rich and –poor settings [8].We 
recruited a cohort of MSM at high risk of HIV-1 acquisition to evaluate potential markers of 
immune activation and identify a potential high-risk immune profile in comparison to men at 
low risk of HIV-1 acquisition.
35 HIV-1 negative self-identified ‘high-risk’ MSM and 34 age- and ethnicity-matched self-
identified ‘healthy, low-risk’ male control subjects were recruited at Fenway Health, 
Massachusetts General Hospital and Brigham and Women's Hospital under IRB-approved 
protocols and included in this study. There was no statistically significant difference in age 
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(unpaired two-tailed t-test: p=0.1) or distribution of ethnicities (Chi-square test for trend: 
p=0.3) between the two groups. Peripheral blood samples were collected and PBMC isolated 
by density gradient centrifugation [9]. Plasma was analyzed for presence of LPS by LAL 
assay (Thermo Scientific, Pittsburgh, PA) and cytokine concentrations by 29-multiplex 
assay (HCYTMAG-60K-PX29, Millipore, Chicago, IL, USA). Plasma LPS was detected in 
5/34 controls and 25/35 MSM (p<0.0001, Fisher's exact test) and levels of plasma endotoxin 
were significantly higher in MSM compared to controls (Figure 1A), but did not associate 
with history of STIs (p=0.9). Furthermore, levels of plasma LPS were inversely correlated 
with time since most recent sexual encounter without condom prior to date of blood draw 
(Figure 1B) and presence of LPS in plasma was associated with increased levels of plasma 
TNFα, Eotaxin, IP-10 and MCP-1 (Figure 1C). No other analytes differed significantly 
between LPS negative and positive MSM. Cells were stained with Fixable Live/Dead Stain, 
anti-CD4 (Invitrogen, Eugene, OR, USA), anti-CD3 (BioLegend, San Diego, CA, USA), 
anti-CD8, anti-CD38, anti-HLA-DR, anti-CD57, anti-CD25, anti-Ki-67 and anti-CD69 (BD 
Biosciences, San Jose, CA) and analyzed by flow cytometry. MSM presented with a 
significantly lower CD4/CD8 ratio compared to controls (Figure 1D). When stratified 
according to LPS levels, MSM with no detectable plasma endotoxin had higher CD4/CD8 T 
cell ratios compared to MSM with detectable plasma endotoxin (Figure 1D). Spearman 
analyses showed a negative correlation between LPS levels and CD4/CD8 ratio (r=-0.5; 
p=0.002). Overall, these data imply an altered immune profile in MSM compared to controls 
as signified by a decreased baseline CD4/CD8 T lymphocyte ratio, which can be indicative 
of systemic immune activation [10] or immune pathology [11].
To obtain a more comprehensive understanding of the differences in immune parameters 
between MSM compared to controls, we combined T cell markers and cytokine responses 
for analysis by partial least squares discriminant analysis (PLSDA) [12]. Ex vivo expression 
of %CD38, %HLA-DR, %CD25, %CD69, %CD57, %Ki67 and plasma cytokine 
concentrations were included in analysis. PLSDA showed separation according to latent 
variable (LV) scores (calibration error average of 0.18 and cross-validation error average of 
0.22), suggesting differential association of various T lymphocytes marker and cytokine 
combinations with respect to MSM versus controls (Figure 1E). Specifically, higher plasma 
concentrations of Eotaxin, MCP-1, IP-10, and elevated bulk %CD8+, %CD57+CD4+ and 
%CD57+CD8+ T cells were observed in MSM, while elevated bulk %CD4+, %CD25+CD8+, 
%CD69+CD8+ and %CD38+CD4+ T cells were observed in controls. Heat map clustering 
using the GENE-E matrix visualization and analysis tool (Broad Institute, Cambridge, MA 
http://www.broadinstitute.org/cancer/software/GENE-E/) resulted in the same separation of 
immune markers for MSM versus controls (Figure 1F). Overall, these data demonstrate 
differential expression of several cytokines and markers of T cell activation and senescence 
in high-risk MSM compared to controls, as well as translocation of immune-activating 
bacterial products into the blood stream associated with decreased CD4/CD8 T cell ratio and 
elevated plasma cytokine concentrations.
In this cohort of MSM, the presence of elevated plasma endotoxin levels was associated 
with recent high-risk sexual encounter, decreased CD4/CD8 T cell ratio and increased 
plasma cytokine concentrations. We observed no difference in bulk %CD3+ T cell 
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populations between MSM and controls, and others have shown that MSM and heterosexual 
men do not differ in their absolute CD4 counts [13]. The observed differences in CD4/CD8 
T cell ratios, as well as elevated plasma cytokine levels and percentages of CD57+CD4+ and 
CD57+CD8+ T cell subsets in MSM might therefore be a reflection of immune activation 
following episodes of intermittent endotoxemia. The latter is supported by data from animal 
studies [14] and might contribute to alterations in immune homeostasis [15-17]. MSM 
furthermore presented with decreased percentages of CD38+CD4+ T cells, a phenotype 
linked to increased proliferative capacity but impaired cytokine production upon stimulation 
[18].
Several lines of evidence in HIV-1-exposed women suggest that enhanced levels of immune 
activation might lead to an increased risk of HIV-1 infection [19], and also be associated 
with faster disease progression should infection occur. Increased levels of TNFα can 
increase the risk of HIV-1 acquisition in women [20], and immune activation set point 
during early HIV-1 infection was shown to predict subsequent CD4+ T cell levels 
independently of viral load [21]. In conclusion, our study identified a subset of MSM with 
plasma endotoxemia and an immune profile suggestive of chronic immune activation and 
immune exhaustion. These immunological changes should be taken into account in future 
vaccination or prevention studies as increased inflammation can represent a risk factor for 
HIV-1 acquisition, as recently shown for seronegative exposed women [20].
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Figure 1. Analysis of Immune Profiles in MSM and controls
A) Plasma samples from MSM (n=35, black circles) and controls (n=34, clear circles) were 
analyzed for endotoxin by LAL assay. Values are presented as endotoxin units (EU)/ml for 
each individual on a log10 scale (EU/ml range: 0-0.71 (controls); 0–101.6 (MSM)). Lowest 
values set for logarithmic graphing is shown by black dotted line (=0.01 EU/ml). B) 
Spearman correlation of LPS levels (EU/ml, log10) versus days since most recent high-risk 
exposure in MSM (n=32). C) Cytokine concentrations in MSM samples were stratified into 
endotoxin negative (n=10) and positive (n=25). Tukey box and whiskers plots of TNFα, 
Eotaxin, IP-10 and MCP-1 concentrations (pg/ml, log2) in endotoxin negative (detection 
limit, light grey boxes) and endotoxin positive (0.03-101.61 EU/ml, dark grey boxes) 
samples showing median, 5-95 percentiles and individual outliers. D) Tukey box and 
whiskers plots of CD4/CD8 ratios and group median for controls (n=34, white box), total 
MSM (n=35, black box) and MSM divided into LPS negative (n=10, light grey box) and 
LPS positive (n=25, dark grey box) with outliers shown. E) T cell marker and cytokine data 
were combined (n= 69) and analyzed by PLSDA comparing MSM with controls. PLSDA 
scores plot showing MSM (n=35, red dots) and controls (n=34, blue dots). F) Heat map 
clustering analysis of immune markers identified by PLSDA. Expression levels are 
displayed on a relative scale (-3 to +3) for each individual marker adjusted to group mean 
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and standard deviation. Statistical significance is indicated as *p<0.05, **p<0.01 and 
***p<0.001.
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